Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII
A biotech born out of the work of Stanford CAR-T leader Crystal Mackall is publicly unveiling its $200 million Series A Wednesday, after already going through a Phase I clinical trial, rebranding and setting up plans for a potential registrational study.
CARGO Therapeutics will enter a Phase II trial later this year with the goal of taking its autologous CD22-targeted CAR-T cell therapy to the FDA’s doorsteps for an approval in large B-cell lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.